Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax
| Autor: | Allyson Price, Alessandra Ferrajoli, Maria Tariq Siddiqui, Gautam Borthakur |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
B cell prolymphocytic leukemia
Tp53 mutation Article Venetoclax chemistry.chemical_compound Complex Karyotype B-cell prolymphocytic leukemia Deletion 17p Medicine Bruton's tyrosine kinase TP53 RC254-282 Minimal Residual Disease Negative biology business.industry Ibrutinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens Hematology medicine.disease MRD Negative Oncology chemistry Cancer research biology.protein business |
| Zdroj: | Leukemia Research Reports, Vol 16, Iss, Pp 100266-(2021) Leukemia Research Reports |
| ISSN: | 2213-0489 |
| DOI: | 10.1016/j.lrr.2021.100266 |
| Popis: | B cell prolymphocytic leukemia is a rare and aggressive disorder often with high risk features including TP53 mutation, deletion 17p and complex karyotype. There is scarcity of data regarding treatment and existing therapies induce short lived remissions. Ibrutinib, a Bruton tyrosine kinase inhibitor, has had success in some patients with high risk features. Venetoclax, a BCL-2 inhibitor, has primarily been used in the relapsed setting. We present a case of B PLL with deletion 17p and mutated TP53 treated with ibrutinib and venetoclax in the frontline setting which resulted in measurable/minimal residual disease negative remission for approximately three years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|